Cargando…
DREADD: A Chemogenetic GPCR Signaling Platform
Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of...
Autores principales: | Zhu, Hu, Roth, Bryan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368861/ https://www.ncbi.nlm.nih.gov/pubmed/25522378 http://dx.doi.org/10.1093/ijnp/pyu007 |
Ejemplares similares
-
The DREADDful Hurdles and Opportunities of the Chronic Chemogenetic Toolbox
por: Claes, Marie, et al.
Publicado: (2022) -
The use of chemogenetic actuator ligands in nonhuman primate DREADDs-fMRI
por: Cushnie, Adriana K., et al.
Publicado: (2022) -
Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice
por: Jendryka, Martin, et al.
Publicado: (2019) -
Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics
por: Weston, Mikail, et al.
Publicado: (2019) -
5-HT(2A) Agonists: A Novel Therapy for Functional Neurological Disorders?
por: Bryson, Alexander, et al.
Publicado: (2017)